Silver Oak Securities Incorporated Purchases Shares of 7,278 AtriCure, Inc. (NASDAQ:ATRC)

Silver Oak Securities Incorporated bought a new position in AtriCure, Inc. (NASDAQ:ATRC) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,278 shares of the medical device company’s stock, valued at approximately $220,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Champlain Investment Partners LLC raised its holdings in AtriCure by 4.3% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock worth $78,253,000 after buying an additional 115,813 shares during the period. Wellington Management Group LLP increased its position in shares of AtriCure by 0.4% in the third quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company’s stock worth $43,291,000 after acquiring an additional 6,045 shares in the last quarter. State Street Corp raised its holdings in shares of AtriCure by 4.9% during the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock valued at $37,710,000 after acquiring an additional 63,002 shares during the period. Geode Capital Management LLC lifted its position in shares of AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock valued at $32,326,000 after acquiring an additional 32,676 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in shares of AtriCure by 14.6% in the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock valued at $18,621,000 after acquiring an additional 84,700 shares in the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Stock Performance

Shares of ATRC opened at $41.00 on Monday. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -49.40 and a beta of 1.46. The company’s fifty day moving average is $35.19 and its 200-day moving average is $30.78. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11.

Analysts Set New Price Targets

ATRC has been the subject of a number of research analyst reports. JPMorgan Chase & Co. restated an “overweight” rating and issued a $40.00 target price on shares of AtriCure in a report on Tuesday, December 17th. Oppenheimer lifted their target price on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Needham & Company LLC increased their price target on shares of AtriCure from $40.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Canaccord Genuity Group boosted their price objective on shares of AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, UBS Group increased their target price on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, AtriCure has a consensus rating of “Moderate Buy” and an average price target of $43.38.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.